Funding, M&A, exec moves and hiring — matched to your market, with the people to call.See plans →
MindMaze Therapeutics secures CHF 4.0 million in initial tranche of Neuro.io equity financing, supporting U.S. commercial priorities and neurotherapeutics platform.
MindMaze Therapeutics has completed the initial tranche of its CHF 8.0 million strategic equity financing with Neuro.io, receiving CHF 4.0 million in gross cash proceeds. In connection with this tranche, 4,970,000 treasury shares were transferred to Neuro.io. The company has revised the funding schedule for the second tranche of CHF 4.0 million. These actions aim to bolster its operations focused on neurology.
Company Information
Company
MindMaze Therapeutics Holding SA
Location
Geneva, Geneva, Switzerland
About
MindMaze Therapeutics is a global leader in brain technology, dedicated to redefining the recovery trajectory for patients with neurological platform-based digital treatments. By integrating advanced software, proprietary sensors, and AI-driven data analytics, MindMaze Therapeutics provides a seamless continuum of care. The Company's FDA-cleared neurotherapeutics address the systemic shortage of specialized clinicians.
Related People
Suggested for you
3 contacts
Verified contactsGangadhar G., Director Corporate Development & Strate… hidden hidden
Predictive Intelligence
Strategic
ML-powered predictions for MindMaze Therapeutics Holding SA's next move
GenevaBiotechnologyHealth CareArtificial IntelligenceMedical